Clinical Trial Update: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers [Phase 2]

View source ↗

Summary

A Phase 2 study (DAREON-5) is evaluating different doses of BI-764532 in people with small cell lung cancer and other neuroendocrine cancers; the trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extra-pulmonary Neuroendocrine Carcinoma
• Neuroendocrine Neoplasms
• Small Cell Lung Cancer

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Small Cell Lung Carcinoma, Neuroendocrine Neoplasms | Phase 2 | Status: RECRUITING